 Taufiq Salahuddin
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 7 | 2023 | 102 | 1.800 |
Why?
| | Coronary Artery Disease | 7 | 2025 | 698 | 1.330 |
Why?
| | Biological Products | 2 | 2023 | 216 | 1.290 |
Why?
| | Cardiovascular Agents | 1 | 2023 | 159 | 0.750 |
Why?
| | May-Thurner Syndrome | 1 | 2020 | 1 | 0.660 |
Why?
| | Iliac Vein | 1 | 2020 | 13 | 0.650 |
Why?
| | Femoral Vein | 1 | 2020 | 34 | 0.640 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 77 | 0.630 |
Why?
| | Angina, Unstable | 1 | 2019 | 76 | 0.630 |
Why?
| | Thrombolytic Therapy | 1 | 2020 | 142 | 0.600 |
Why?
| | Plaque, Atherosclerotic | 2 | 2017 | 57 | 0.580 |
Why?
| | Venous Thrombosis | 1 | 2020 | 190 | 0.560 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2531 | 0.550 |
Why?
| | Coronary Disease | 1 | 2019 | 385 | 0.540 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 270 | 0.540 |
Why?
| | Endovascular Procedures | 1 | 2021 | 312 | 0.520 |
Why?
| | Vascular Surgical Procedures | 1 | 2020 | 303 | 0.520 |
Why?
| | Peripheral Arterial Disease | 2 | 2021 | 475 | 0.520 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 279 | 0.500 |
Why?
| | Stroke | 3 | 2019 | 1120 | 0.490 |
Why?
| | Heart Failure | 3 | 2025 | 2236 | 0.470 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1046 | 0.460 |
Why?
| | Vascular Calcification | 1 | 2015 | 108 | 0.420 |
Why?
| | Cholesterol | 1 | 2015 | 410 | 0.410 |
Why?
| | Veterans | 1 | 2023 | 1476 | 0.370 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 82 | 0.370 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2111 | 0.350 |
Why?
| | Hospitalization | 1 | 2019 | 2199 | 0.320 |
Why?
| | Atrial Fibrillation | 3 | 2016 | 388 | 0.270 |
Why?
| | Ultrasonography, Interventional | 1 | 2025 | 141 | 0.210 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 213 | 0.200 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1291 | 0.200 |
Why?
| | Biological Therapy | 1 | 2023 | 29 | 0.200 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 746 | 0.200 |
Why?
| | Cause of Death | 2 | 2023 | 434 | 0.200 |
Why?
| | Humans | 22 | 2025 | 137585 | 0.190 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 135 | 0.190 |
Why?
| | Quality Indicators, Health Care | 1 | 2025 | 307 | 0.190 |
Why?
| | Women's Health | 1 | 2025 | 372 | 0.190 |
Why?
| | Freedom | 1 | 2021 | 14 | 0.180 |
Why?
| | Risk Factors | 10 | 2025 | 10388 | 0.180 |
Why?
| | Limb Salvage | 1 | 2021 | 57 | 0.180 |
Why?
| | Social Class | 1 | 2023 | 282 | 0.180 |
Why?
| | Neutrophils | 2 | 2018 | 1238 | 0.180 |
Why?
| | Inflammation | 4 | 2018 | 2837 | 0.160 |
Why?
| | Sodium | 1 | 2020 | 217 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 480 | 0.160 |
Why?
| | Esters | 1 | 2019 | 76 | 0.160 |
Why?
| | Amides | 1 | 2019 | 93 | 0.160 |
Why?
| | Cholesterol, HDL | 1 | 2019 | 203 | 0.150 |
Why?
| | Veterans Health | 1 | 2020 | 186 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1289 | 0.150 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2018 | 135 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 4 | 2017 | 2691 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 617 | 0.150 |
Why?
| | Middle Aged | 12 | 2025 | 33479 | 0.140 |
Why?
| | Ischemia | 1 | 2021 | 409 | 0.140 |
Why?
| | Anticholesteremic Agents | 1 | 2019 | 153 | 0.140 |
Why?
| | Sulfhydryl Compounds | 1 | 2019 | 189 | 0.140 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2019 | 611 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1468 | 0.130 |
Why?
| | United States | 7 | 2025 | 14841 | 0.130 |
Why?
| | Retrospective Studies | 3 | 2025 | 15657 | 0.130 |
Why?
| | Inflammation Mediators | 2 | 2016 | 513 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2017 | 120 | 0.130 |
Why?
| | Atrial Remodeling | 1 | 2016 | 9 | 0.130 |
Why?
| | Atrial Function, Left | 1 | 2016 | 7 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2019 | 3556 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 951 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1313 | 0.120 |
Why?
| | Aorta | 1 | 2018 | 417 | 0.120 |
Why?
| | Aortitis | 1 | 2015 | 10 | 0.120 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 242 | 0.120 |
Why?
| | Neutrophil Activation | 1 | 2015 | 80 | 0.120 |
Why?
| | Glucose | 1 | 2020 | 1020 | 0.120 |
Why?
| | Prospective Studies | 6 | 2018 | 7604 | 0.120 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 178 | 0.110 |
Why?
| | Cardiomegaly | 1 | 2016 | 175 | 0.110 |
Why?
| | Multimodal Imaging | 1 | 2015 | 113 | 0.110 |
Why?
| | Atrial Premature Complexes | 1 | 2014 | 3 | 0.110 |
Why?
| | Aged | 8 | 2025 | 23961 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 294 | 0.110 |
Why?
| | Female | 15 | 2025 | 73304 | 0.110 |
Why?
| | Ventricular Premature Complexes | 1 | 2014 | 36 | 0.110 |
Why?
| | DNA Modification Methylases | 1 | 2013 | 17 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2018 | 415 | 0.110 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 28 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1477 | 0.100 |
Why?
| | Male | 14 | 2025 | 67762 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2016 | 243 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4030 | 0.100 |
Why?
| | Human papillomavirus 16 | 1 | 2013 | 35 | 0.100 |
Why?
| | Positron Emission Tomography Computed Tomography | 3 | 2018 | 98 | 0.100 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2013 | 63 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2025 | 10811 | 0.100 |
Why?
| | Self Report | 1 | 2016 | 827 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 327 | 0.090 |
Why?
| | Interleukin-10 | 1 | 2013 | 302 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2015 | 762 | 0.080 |
Why?
| | Biomarkers | 3 | 2016 | 4149 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 325 | 0.080 |
Why?
| | Incidence | 3 | 2025 | 2804 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2426 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 683 | 0.070 |
Why?
| | Depression | 1 | 2016 | 1397 | 0.070 |
Why?
| | Computed Tomography Angiography | 2 | 2018 | 129 | 0.060 |
Why?
| | Coronary Angiography | 2 | 2018 | 317 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 2031 | 0.060 |
Why?
| | Hospitals, Veterans | 1 | 2025 | 252 | 0.050 |
Why?
| | Postmenopause | 1 | 2025 | 366 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 5472 | 0.050 |
Why?
| | Cohort Studies | 3 | 2017 | 5742 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 612 | 0.050 |
Why?
| | Electrocardiography | 2 | 2015 | 629 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3457 | 0.050 |
Why?
| | Comorbidity | 2 | 2016 | 1622 | 0.040 |
Why?
| | Time Factors | 2 | 2025 | 6828 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2016 | 7635 | 0.040 |
Why?
| | Adult | 6 | 2018 | 37929 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2671 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2828 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 199 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3284 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 282 | 0.030 |
Why?
| | Quality Improvement | 1 | 2025 | 1178 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 37 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 392 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 375 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 452 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 329 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2016 | 224 | 0.030 |
Why?
| | Coronary Vessels | 1 | 2016 | 248 | 0.030 |
Why?
| | Genes, Recessive | 1 | 2013 | 78 | 0.030 |
Why?
| | Echocardiography | 1 | 2016 | 642 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 445 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2014 | 266 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1509 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1266 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1972 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 341 | 0.020 |
Why?
| | Risk | 1 | 2014 | 912 | 0.020 |
Why?
| | Regression Analysis | 1 | 2013 | 1024 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1070 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 600 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2015 | 828 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3196 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2734 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 493 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 1250 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2844 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5131 | 0.020 |
Why?
| | Genetic Variation | 1 | 2013 | 991 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.010 |
Why?
|
|
Salahuddin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|